Skip to main content

Cabazitaxel Side Effects

Medically reviewed by Last updated on Jan 27, 2024.

Applies to cabazitaxel: intravenous solution.


Intravenous route (Solution)

NeutropeniaNeutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. Cabazitaxel is contraindicated in patients with neutrophil counts of less than or equal to 1500 cells/mm(3). Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m(2).Severe HypersensitivitySevere hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the cabazitaxel infusion and administration of appropriate therapy. Patients should receive premedication. Cabazitaxel is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to drugs formulated with polysorbate 80.

Serious side effects of Cabazitaxel

Along with its needed effects, cabazitaxel may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cabazitaxel:

More common

Less common

Incidence not known

Other side effects of Cabazitaxel

Some side effects of cabazitaxel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to cabazitaxel: intravenous solution.


The most common adverse events were anemia, leukopenia, neutropenia, thrombocytopenia, and diarrhea.[Ref]


Very common (10% or more): Anemia (98%), leukopenia (96%), neutropenia (94%), thrombocytopenia (48%)

Common (1% to 10%): Febrile neutropenia[Ref]


Very common (10% or more): Diarrhea (47%), nausea (34%), vomiting (22%), constipation (20%), abdominal pain (17%), dyspepsia (10%)

Common (1% to 10%): Abdominal pain upper, hemorrhoids, gastroesophageal reflux disease, rectal hemorrhage, dry mouth, abdominal distension

Frequency not reported: Death related to diarrhea and electrolyte imbalance, GI hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, colitis

Postmarketing reports: Gastritis, intestinal obstruction[Ref]

Nervous system

Very common (10% or more): Fatigue (37%), dysgeusia (11%)

Common (1% to 10%): Dizziness, peripheral neuropathy, headache, peripheral sensory neuropathy, paresthesia, lethargy, hypoesthesia, tinnitus, vertigo, sciatica

Frequency not reported: Peripheral motor neuropathy, fatal cerebral hemorrhage[Ref]


Very common (10% or more): Asthenia (20%), pyrexia (12%)

Common (1% to 10%): Mucosal inflammation, pain, death due to causes other than disease progression, malaise[Ref]


Very common (10% or more): Dyspnea (12%), cough (11%)

Common (1% to 10%): Oropharyngeal pain[Ref]


Common (1% to 10%): Peripheral edema, arrhythmia, hypotension, deep vein thrombosis, hypertension, tachycardia, grade 3 or higher arrhythmias, orthostatic hypotension, hot flush, flushing, atrial fibrillation

Uncommon (0.1% to 1%): Cardiac failure, cardiac arrest, fatal ventricular fibrillation[Ref]


Uncommon (0.1% to 1%): Grade 3 to 4 increased AST, grade 3 to 4 increased ALT, increased bilirubin

Frequency not reported: Fatal renal failure[Ref]


Very common (10% or more): Anorexia (16%)

Common (1% to 10%): Weight decreased, dehydration, edema, hyperglycemia, hypokalemia[Ref]


Very common (10% or more): Hematuria (17%)

Common (1% to 10%): Dysuria, pollakiuria, urinary retention, urinary incontinence, ureteric obstruction, pelvic pain[Ref]


Common (1% to 10%): AST increased, transaminases increased

Uncommon (0.1% to 1%): ALT increased, bilirubin increased[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Very common (10% or more): Back pain (16%), arthralgia (10.5%)

Common (1% to 10%): Pain in extremity, muscle spasms, myalgia, musculoskeletal chest pain, flank pain, chills[Ref]


Common (1% to 10%): Urinary tract infection, influenza, cystitis, upper respiratory tract infection, pneumonia, cellulitis, herpes zoster, septic shock, sepsis, candidiasis

Uncommon (0.1% to 1%): Neutropenic sepsis, neutropenic infections

Frequency not reported: Fatal infection[Ref]


Very common (10% or more): Alopecia (10%)

Common (1% to 10%): Dry skin, erythema[Ref]


Common (1% to 10%): Conjunctivitis, increased lacrimation[Ref]


Common (1% to 10%): Anxiety, confusional state[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Jevtana (cabazitaxel). sanofi-aventis. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.